Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

Aquestive Therapeutics Provides Business Update

GlobeNewswire October 9, 2023

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire September 20, 2023

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant(TM) (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

GlobeNewswire September 11, 2023

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire August 23, 2023

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 7, 2023

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 2, 2023

Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm(TM) (epinephrine) Sublingual Film

GlobeNewswire July 27, 2023

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

GlobeNewswire July 25, 2023

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (TM) (epinephrine) Sublingual Film at Aspen Allergy Conference

GlobeNewswire July 25, 2023

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm(TM) (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit

GlobeNewswire July 6, 2023

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

GlobeNewswire June 29, 2023

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm (TM) (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

GlobeNewswire May 31, 2023

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 2, 2023

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire April 26, 2023

Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm(TM) for Lead Candidate AQST-109 (Epinephrine Sublingual Film)

GlobeNewswire April 20, 2023

Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET

GlobeNewswire April 18, 2023

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant(TM) (diazepam) Buccal Film to Additional Global Markets

GlobeNewswire March 29, 2023

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

GlobeNewswire March 7, 2023

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 1, 2023

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

GlobeNewswire February 22, 2023